The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries
Open accessAbstract
BACKGROUND: The Xpert MTB/RIF assay has garnered significant interest as a sensitive and rapid diagnostic tool to improve detection of sensitive and drug resistant tuberculosis. However, most existing literature has described the performance of MTB/RIF testing only in study conditions; little information is available on its use in routine case finding. TB REACH is a multi-country initiative focusing on innovative ways to improve case notification. METHODS: We selected a convenience sample of nine TB REACH projects for inclusion to cover a range of implementers, regions and approaches. Standard quarterly reports and machine data from the first 12 months of MTB/RIF implementation in each project were utilized to analyze patient yields, rifampicin resistance, and failed tests. Data was collected from September 2011 to March 2013. A questionnaire was implemented and semi-structured interviews with project staff were conducted to gather information on user experiences and challenges. RESULTS: All projects used MTB/RIF testing for people with suspected TB, as opposed to testing for drug resistance among already diagnosed patients. The projects placed 65 machines (196 modules) in a variety of facilities and employed numerous case-finding strategies and testing algorithms. The projects consumed 47,973 MTB/RIF tests. Of valid tests, 7,195 (16.8%) were positive for MTB. A total of 982 rifampicin resistant results were found (13.6% of positive tests). Of all tests conducted, 10.6% failed. The need for continuous power supply was noted by all projects and most used locally procured solutions. There was considerable heterogeneity in how results were reported and recorded, reflecting the lack of standardized guidance in some countries. CONCLUSIONS: The findings of this study begin to fill the gaps among guidelines, research findings, and real-world implementation of MTB/RIF testing. Testing with Xpert MTB/RIF detected a large number of people with TB that routine services failed to detect. The study demonstrates the versatility and impact of the technology, but also outlines various surmountable barriers to implementation. The study is not representative of all early implementer experiences with MTB/RIF testing but rather provides an overview of the shared issues as well as the many different approaches to programmatic MTB/RIF implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Sohn, H., Schiller, I., Kloda, L. A., Boehme, C. C., Pai, M., & Dendukuri, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub2 · Cited by 253
Xpert MTB/RIF Assay for Diagnosis of Pleural Tuberculosis
Friedrich, S. O., von Groote-Bidlingmaier, F., & Diacon, A. H. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05454-11 · Cited by 126
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Cost–effectiveness thresholds: pros and cons
Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164418 · Cited by 783
Albert, H., Nathavitharana, R. R., Isaacs, C., Pai, M., Denkinger, C. M., & Boehme, C. C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00543-2016 · Cited by 300
Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects
Pai, M., & Schito, M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu803 · Cited by 193
Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
Metadata
- Authors
- Creswell, J., Codlin, A. J., Andre, E., Micek, M. A., Bedru, A., Carter, E. J., Yadav, R.-P., Mosneaga, A., Rai, B., Banu, S., Brouwer, M., Blok, L., Sahu, S., & Ditiu, L.
- Venue
- BMC Infectious Diseases
- Published
- 2014-01-02
- Volume
- 14
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W1988898295
- Cited by
- 175
- References
- 3
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. https://app.cochat.ai/papers/10.1186/1471-2334-14-2
- The paper
- Creswell, J., Codlin, A. J., Andre, E., Micek, M. A., Bedru, A., Carter, E. J., Yadav, R.-P., Mosneaga, A., Rai, B., Banu, S., Brouwer, M., Blok, L., Sahu, S., & Ditiu, L. (2014). Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-14-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.